Citadel Advisors’s Cytek Biosciences CTKB Stock Holding History

Citadel Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,900	Closed	-$19.6K	–	12900
2025 Q1	$19.6K	Buy	+4,900	New	+$25.4K	﹤0.01%	13160
2024 Q3	–	Sell	-100	Closed	-$558	–	14357
2024 Q2	$558	Buy	+100	New	+$601	﹤0.01%	13963
2023 Q4	–	Sell	-9,300	Closed	-$51.3K	–	14378
2023 Q3	$51.3K	Buy	9,300 +5,700	+158%	+$45.7K	﹤0.01%	11734
2023 Q2	$30.7K	Buy	3,600 +3,500	+3,500%	+$31.4K	﹤0.01%	12329
2023 Q1	$919	Sell	100 -200	-67%	-$2.15K	﹤0.01%	14399
2022 Q4	$3.06K	Buy	+300	New	+$4.03K	﹤0.01%	14255

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors's CTKB Position: Q1 2026 in Review

Citadel Advisors increased its Cytek Biosciences (CTKB) stake by 183% in Q1 2026, buying an estimated $1.44M and bringing the position to 471,392 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #6008.

Citadel Advisors first reported a position in CTKB in Q3 2021 and has held it in 16 quarters since. The position peaked at $3.61M in Q1 2023. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

Citadel Advisors held 471,392 shares of Cytek Biosciences worth $2.06M as of Q1 2026.
Citadel Advisors bought 304,638 Cytek Biosciences shares in Q1 2026, an estimated $1.44M.
Cytek Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6008 holding.
Citadel Advisors first reported a position in Cytek Biosciences in Q3 2021 and has held it in 16 quarters since.
Citadel Advisors's Cytek Biosciences position peaked at $3.61M in Q1 2023.
165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.